#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Oxidative Modification of rRNA
1-1	0-2	2.	_	_	_	_
1-2	3-12	Oxidative	person|abstract[2]	new|new[2]	coref	5-17
1-3	13-25	Modification	abstract[2]	new[2]	_	_
1-4	26-28	of	abstract[2]	new[2]	_	_
1-5	29-33	rRNA	abstract[2]|abstract	new[2]|new	coref	2-1

#Text=rRNA constitutes the structural and functional core of the ribosome .
2-1	34-38	rRNA	abstract	giv	coref	9-17
2-2	39-50	constitutes	_	_	_	_
2-3	51-54	the	abstract[5]	new[5]	_	_
2-4	55-65	structural	abstract[5]	new[5]	_	_
2-5	66-69	and	abstract[5]	new[5]	_	_
2-6	70-80	functional	abstract[5]	new[5]	_	_
2-7	81-85	core	abstract[5]	new[5]	_	_
2-8	86-88	of	abstract[5]	new[5]	_	_
2-9	89-92	the	abstract[5]|object[6]	new[5]|new[6]	coref	9-2[0_6]
2-10	93-101	ribosome	abstract[5]|object[6]	new[5]|new[6]	_	_
2-11	102-103	.	_	_	_	_

#Text=ROS can affect RNA in a multitude of ways , including chemical modification of the base and sugar moieties , generation of abasic sites , and strand breaks .
3-1	104-107	ROS	substance	new	coref	11-29[85_0]
3-2	108-111	can	_	_	_	_
3-3	112-118	affect	_	_	_	_
3-4	119-122	RNA	substance	new	coref	7-10
3-5	123-125	in	_	_	_	_
3-6	126-127	a	abstract[9]	new[9]	_	_
3-7	128-137	multitude	abstract[9]	new[9]	_	_
3-8	138-140	of	abstract[9]	new[9]	_	_
3-9	141-145	ways	abstract[9]|abstract	new[9]|new	_	_
3-10	146-147	,	abstract[9]	new[9]	_	_
3-11	148-157	including	abstract[9]	new[9]	_	_
3-12	158-166	chemical	abstract[9]|abstract[11]	new[9]|new[11]	coref	21-15[175_11]
3-13	167-179	modification	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-14	180-182	of	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-15	183-186	the	abstract[9]|abstract[11]|place[12]	new[9]|new[11]|new[12]	coref	6-22[37_12]
3-16	187-191	base	abstract[9]|abstract[11]|place[12]	new[9]|new[11]|new[12]	_	_
3-17	192-195	and	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-18	196-201	sugar	abstract[9]|abstract[11]|substance|substance[14]	new[9]|new[11]|new|new[14]	_	_
3-19	202-210	moieties	abstract[9]|abstract[11]|substance[14]	new[9]|new[11]|new[14]	_	_
3-20	211-212	,	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-21	213-223	generation	abstract[9]|abstract[11]|abstract[15]	new[9]|new[11]|new[15]	_	_
3-22	224-226	of	abstract[9]|abstract[11]|abstract[15]	new[9]|new[11]|new[15]	_	_
3-23	227-233	abasic	abstract[9]|abstract[11]|abstract[15]|abstract|place[17]	new[9]|new[11]|new[15]|new|new[17]	_	_
3-24	234-239	sites	abstract[9]|abstract[11]|abstract[15]|place[17]	new[9]|new[11]|new[15]|new[17]	_	_
3-25	240-241	,	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-26	242-245	and	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-27	246-252	strand	abstract[9]|abstract[11]|place|event[19]	new[9]|new[11]|new|new[19]	_	_
3-28	253-259	breaks	abstract[9]|abstract[11]|event[19]	new[9]|new[11]|new[19]	_	_
3-29	260-261	.	_	_	_	_

#Text=Guanine is the most easily oxidized nucleobase and best studied in this respect .
4-1	262-269	Guanine	substance	new	coref	4-3[21_0]
4-2	270-272	is	_	_	_	_
4-3	273-276	the	substance[21]	giv[21]	coref	5-5[0_21]
4-4	277-281	most	substance[21]	giv[21]	_	_
4-5	282-288	easily	substance[21]	giv[21]	_	_
4-6	289-297	oxidized	substance[21]	giv[21]	_	_
4-7	298-308	nucleobase	substance[21]	giv[21]	_	_
4-8	309-312	and	_	_	_	_
4-9	313-317	best	_	_	_	_
4-10	318-325	studied	_	_	_	_
4-11	326-328	in	_	_	_	_
4-12	329-333	this	abstract[22]	new[22]	_	_
4-13	334-341	respect	abstract[22]	new[22]	_	_
4-14	342-343	.	_	_	_	_

#Text=An oxidized form of guanine , 8-oxo-7,8-dihydroguanine ( 8-hydroxyguanine ; 8-oxo-G ) , is a ubiquitous oxidative lesion , readily detectable in cellular nucleic acids .
5-1	344-346	An	abstract[23]	new[23]	coref	5-15[29_23]
5-2	347-355	oxidized	abstract[23]	new[23]	_	_
5-3	356-360	form	abstract[23]	new[23]	_	_
5-4	361-363	of	abstract[23]	new[23]	_	_
5-5	364-371	guanine	abstract[23]|substance	new[23]|giv	appos	5-7
5-6	372-373	,	_	_	_	_
5-7	374-398	8-oxo-7,8-dihydroguanine	substance	giv	appos	5-9
5-8	399-400	(	_	_	_	_
5-9	401-417	8-hydroxyguanine	substance	giv	_	_
5-10	418-419	;	_	_	_	_
5-11	420-427	8-oxo-G	abstract	new	coref	6-6
5-12	428-429	)	_	_	_	_
5-13	430-431	,	_	_	_	_
5-14	432-434	is	_	_	_	_
5-15	435-436	a	abstract[29]	giv[29]	_	_
5-16	437-447	ubiquitous	abstract[29]	giv[29]	_	_
5-17	448-457	oxidative	person|abstract[29]	giv|giv[29]	coref	12-28
5-18	458-464	lesion	abstract[29]	giv[29]	_	_
5-19	465-466	,	_	_	_	_
5-20	467-474	readily	_	_	_	_
5-21	475-485	detectable	_	_	_	_
5-22	486-488	in	_	_	_	_
5-23	489-497	cellular	substance[30]	new[30]	_	_
5-24	498-505	nucleic	substance[30]	new[30]	_	_
5-25	506-511	acids	substance[30]	new[30]	_	_
5-26	512-513	.	_	_	_	_

#Text=When present in mRNA , 8-oxo-G interferes with decoding , possibly through the formation of a Hoogsteen pair with adenine when the base rotates around the N-glycosidic bond .
6-1	514-518	When	_	_	_	_
6-2	519-526	present	_	_	_	_
6-3	527-529	in	_	_	_	_
6-4	530-534	mRNA	substance	new	_	_
6-5	535-536	,	_	_	_	_
6-6	537-544	8-oxo-G	abstract	giv	coref	8-10
6-7	545-555	interferes	_	_	_	_
6-8	556-560	with	_	_	_	_
6-9	561-569	decoding	abstract	new	_	_
6-10	570-571	,	_	_	_	_
6-11	572-580	possibly	event[34]	new[34]	_	_
6-12	581-588	through	event[34]	new[34]	_	_
6-13	589-592	the	event[34]	new[34]	_	_
6-14	593-602	formation	event[34]	new[34]	_	_
6-15	603-605	of	event[34]	new[34]	_	_
6-16	606-607	a	event[34]|plant[35]	new[34]|new[35]	_	_
6-17	608-617	Hoogsteen	event[34]|plant[35]	new[34]|new[35]	_	_
6-18	618-622	pair	event[34]|plant[35]	new[34]|new[35]	_	_
6-19	623-627	with	event[34]|plant[35]	new[34]|new[35]	_	_
6-20	628-635	adenine	event[34]|plant[35]|substance	new[34]|new[35]|new	_	_
6-21	636-640	when	_	_	_	_
6-22	641-644	the	place[37]	giv[37]	_	_
6-23	645-649	base	place[37]	giv[37]	_	_
6-24	650-657	rotates	_	_	_	_
6-25	658-664	around	_	_	_	_
6-26	665-668	the	object[39]	new[39]	_	_
6-27	669-681	N-glycosidic	person|object[39]	new|new[39]	_	_
6-28	682-686	bond	object[39]	new[39]	_	_
6-29	687-688	.	_	_	_	_

#Text=The altered base-pairing capacity of 8-oxo-G can also perturb RNA folding .
7-1	689-692	The	abstract[40]	new[40]	_	_
7-2	693-700	altered	abstract[40]	new[40]	_	_
7-3	701-713	base-pairing	abstract[40]	new[40]	_	_
7-4	714-722	capacity	abstract[40]	new[40]	_	_
7-5	723-725	of	abstract[40]	new[40]	_	_
7-6	726-733	8-oxo-G	abstract[40]|person	new[40]|new	_	_
7-7	734-737	can	_	_	_	_
7-8	738-742	also	_	_	_	_
7-9	743-750	perturb	_	_	_	_
7-10	751-754	RNA	substance|abstract[43]	giv|new[43]	coref	8-15
7-11	755-762	folding	abstract[43]	new[43]	_	_
7-12	763-764	.	_	_	_	_

#Text=A recent study revealed a variety of outcomes when 8-oxo-G was incorporated into model RNA substrates , from stabilization of existing structural motifs to their destabilization and rearrangements into new structures .
8-1	765-766	A	abstract[44]	new[44]	coref	13-2[100_44]
8-2	767-773	recent	abstract[44]	new[44]	_	_
8-3	774-779	study	abstract[44]	new[44]	_	_
8-4	780-788	revealed	_	_	_	_
8-5	789-790	a	abstract[45]	new[45]	_	_
8-6	791-798	variety	abstract[45]	new[45]	_	_
8-7	799-801	of	abstract[45]	new[45]	_	_
8-8	802-810	outcomes	abstract[45]|abstract	new[45]|new	ana	8-25
8-9	811-815	when	_	_	_	_
8-10	816-823	8-oxo-G	abstract	giv	coref	13-20
8-11	824-827	was	_	_	_	_
8-12	828-840	incorporated	_	_	_	_
8-13	841-845	into	_	_	_	_
8-14	846-851	model	object[49]	new[49]	_	_
8-15	852-855	RNA	substance|object[49]	giv|new[49]	coref	11-13
8-16	856-866	substrates	object[49]	new[49]	_	_
8-17	867-868	,	_	_	_	_
8-18	869-873	from	_	_	_	_
8-19	874-887	stabilization	abstract	new	_	_
8-20	888-890	of	_	_	_	_
8-21	891-899	existing	_	_	_	_
8-22	900-910	structural	object[51]	new[51]	_	_
8-23	911-917	motifs	object[51]	new[51]	_	_
8-24	918-920	to	_	_	_	_
8-25	921-926	their	abstract|abstract[53]	giv|new[53]	_	_
8-26	927-942	destabilization	abstract[53]	new[53]	_	_
8-27	943-946	and	_	_	_	_
8-28	947-961	rearrangements	abstract[54]	new[54]	_	_
8-29	962-966	into	abstract[54]	new[54]	_	_
8-30	967-970	new	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-31	971-981	structures	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-32	982-983	.	_	_	_	_

#Text=Since ribosome activities in translation depend on many precisely tuned conformational changes and movements within its rRNA framework , oxidation of the bases that are critical for maintaining the correct rRNA structure may impair ribosome functions .
9-1	984-989	Since	_	_	_	_
9-2	990-998	ribosome	object|abstract[57]	giv|new[57]	coref	9-35
9-3	999-1009	activities	abstract[57]	new[57]	_	_
9-4	1010-1012	in	abstract[57]	new[57]	_	_
9-5	1013-1024	translation	abstract[57]|abstract	new[57]|new	ana	9-16
9-6	1025-1031	depend	_	_	_	_
9-7	1032-1034	on	_	_	_	_
9-8	1035-1039	many	abstract[59]	new[59]	_	_
9-9	1040-1049	precisely	abstract[59]	new[59]	_	_
9-10	1050-1055	tuned	abstract[59]	new[59]	_	_
9-11	1056-1070	conformational	abstract[59]	new[59]	_	_
9-12	1071-1078	changes	abstract[59]	new[59]	_	_
9-13	1079-1082	and	_	_	_	_
9-14	1083-1092	movements	abstract[60]	new[60]	_	_
9-15	1093-1099	within	abstract[60]	new[60]	_	_
9-16	1100-1103	its	abstract[60]|abstract|object[63]	new[60]|giv|new[63]	_	_
9-17	1104-1108	rRNA	abstract[60]|abstract|object[63]	new[60]|giv|new[63]	coref	9-31
9-18	1109-1118	framework	abstract[60]|object[63]	new[60]|new[63]	_	_
9-19	1119-1120	,	_	_	_	_
9-20	1121-1130	oxidation	event[64]	new[64]	coref	10-14[0_64]
9-21	1131-1133	of	event[64]	new[64]	_	_
9-22	1134-1137	the	event[64]|abstract[65]	new[64]|new[65]	_	_
9-23	1138-1143	bases	event[64]|abstract[65]	new[64]|new[65]	_	_
9-24	1144-1148	that	_	_	_	_
9-25	1149-1152	are	_	_	_	_
9-26	1153-1161	critical	_	_	_	_
9-27	1162-1165	for	_	_	_	_
9-28	1166-1177	maintaining	_	_	_	_
9-29	1178-1181	the	abstract[67]	new[67]	_	_
9-30	1182-1189	correct	abstract[67]	new[67]	_	_
9-31	1190-1194	rRNA	place|abstract[67]	giv|new[67]	coref	11-8[79_0]
9-32	1195-1204	structure	abstract[67]	new[67]	_	_
9-33	1205-1208	may	_	_	_	_
9-34	1209-1215	impair	_	_	_	_
9-35	1216-1224	ribosome	object|abstract[69]	giv|new[69]	coref	10-25[76_0]
9-36	1225-1234	functions	abstract[69]	new[69]	_	_
9-37	1235-1236	.	_	_	_	_

#Text=It seems therefore likely that the need to withstand a certain degree of oxidation was one of the forces in shaping the evolution of the ribosome .
10-1	1237-1239	It	_	_	_	_
10-2	1240-1245	seems	_	_	_	_
10-3	1246-1255	therefore	_	_	_	_
10-4	1256-1262	likely	_	_	_	_
10-5	1263-1267	that	_	_	_	_
10-6	1268-1271	the	abstract[70]	new[70]	_	_
10-7	1272-1276	need	abstract[70]	new[70]	_	_
10-8	1277-1279	to	_	_	_	_
10-9	1280-1289	withstand	_	_	_	_
10-10	1290-1291	a	abstract[71]	new[71]	_	_
10-11	1292-1299	certain	abstract[71]	new[71]	_	_
10-12	1300-1306	degree	abstract[71]	new[71]	_	_
10-13	1307-1309	of	abstract[71]	new[71]	_	_
10-14	1310-1319	oxidation	abstract[71]|event	new[71]|giv	coref	12-4[89_0]
10-15	1320-1323	was	_	_	_	_
10-16	1324-1327	one	abstract[73]	new[73]	_	_
10-17	1328-1330	of	abstract[73]	new[73]	_	_
10-18	1331-1334	the	abstract[73]|abstract[74]	new[73]|new[74]	_	_
10-19	1335-1341	forces	abstract[73]|abstract[74]	new[73]|new[74]	_	_
10-20	1342-1344	in	_	_	_	_
10-21	1345-1352	shaping	_	_	_	_
10-22	1353-1356	the	abstract[75]	new[75]	_	_
10-23	1357-1366	evolution	abstract[75]	new[75]	_	_
10-24	1367-1369	of	abstract[75]	new[75]	_	_
10-25	1370-1373	the	abstract[75]|object[76]	new[75]|giv[76]	_	_
10-26	1374-1382	ribosome	abstract[75]|object[76]	new[75]|giv[76]	_	_
10-27	1383-1384	.	_	_	_	_

#Text=A striking disappearance of many guanines from mitochondrial rRNA and reduced overall RNA content may be two such evolutionary adaptations that “ hardened ” mitoribosomes against damage from the abundant ROS generated inside mitochondria .
11-1	1385-1386	A	abstract[77]	new[77]	_	_
11-2	1387-1395	striking	abstract[77]	new[77]	_	_
11-3	1396-1409	disappearance	abstract[77]	new[77]	_	_
11-4	1410-1412	of	abstract[77]	new[77]	_	_
11-5	1413-1417	many	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-6	1418-1426	guanines	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-7	1427-1431	from	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-8	1432-1445	mitochondrial	abstract[77]|substance[78]|abstract[79]	new[77]|new[78]|giv[79]	coref	13-28[0_79]
11-9	1446-1450	rRNA	abstract[77]|substance[78]|abstract[79]	new[77]|new[78]|giv[79]	_	_
11-10	1451-1454	and	_	_	_	_
11-11	1455-1462	reduced	abstract[81]	new[81]	coref	11-17[82_81]
11-12	1463-1470	overall	abstract[81]	new[81]	_	_
11-13	1471-1474	RNA	substance|abstract[81]	giv|new[81]	coref	12-5
11-14	1475-1482	content	abstract[81]	new[81]	_	_
11-15	1483-1486	may	_	_	_	_
11-16	1487-1489	be	_	_	_	_
11-17	1490-1493	two	abstract[82]	giv[82]	coref	17-1[131_82]
11-18	1494-1498	such	abstract[82]	giv[82]	_	_
11-19	1499-1511	evolutionary	abstract[82]	giv[82]	_	_
11-20	1512-1523	adaptations	abstract[82]	giv[82]	_	_
11-21	1524-1528	that	_	_	_	_
11-22	1529-1530	“	_	_	_	_
11-23	1531-1539	hardened	_	_	_	_
11-24	1540-1541	”	_	_	_	_
11-25	1542-1555	mitoribosomes	object[83]	new[83]	_	_
11-26	1556-1563	against	object[83]	new[83]	_	_
11-27	1564-1570	damage	object[83]|abstract[84]	new[83]|new[84]	coref	12-27[95_84]
11-28	1571-1575	from	object[83]|abstract[84]	new[83]|new[84]	_	_
11-29	1576-1579	the	object[83]|abstract[84]|substance[85]	new[83]|new[84]|giv[85]	_	_
11-30	1580-1588	abundant	object[83]|abstract[84]|substance[85]	new[83]|new[84]|giv[85]	_	_
11-31	1589-1592	ROS	object[83]|abstract[84]|substance[85]	new[83]|new[84]|giv[85]	_	_
11-32	1593-1602	generated	_	_	_	_
11-33	1603-1609	inside	_	_	_	_
11-34	1610-1622	mitochondria	object	new	_	_
11-35	1623-1624	.	_	_	_	_

#Text=The extent of cellular RNA oxidation was reported to exceed that of DNA when cells were directly treated with H2O2 or subjected to conditions that induce secondary oxidative damage , such as UVA irradiation and ammonia overload .
12-1	1625-1628	The	abstract[87]	new[87]	_	_
12-2	1629-1635	extent	abstract[87]	new[87]	_	_
12-3	1636-1638	of	abstract[87]	new[87]	_	_
12-4	1639-1647	cellular	abstract[87]|event[89]	new[87]|giv[89]	_	_
12-5	1648-1651	RNA	abstract[87]|substance|event[89]	new[87]|giv|giv[89]	coref	13-24
12-6	1652-1661	oxidation	abstract[87]|event[89]	new[87]|giv[89]	_	_
12-7	1662-1665	was	_	_	_	_
12-8	1666-1674	reported	_	_	_	_
12-9	1675-1677	to	_	_	_	_
12-10	1678-1684	exceed	_	_	_	_
12-11	1685-1689	that	_	_	_	_
12-12	1690-1692	of	_	_	_	_
12-13	1693-1696	DNA	substance	new	_	_
12-14	1697-1701	when	_	_	_	_
12-15	1702-1707	cells	object	new	coref	13-7[102_0]
12-16	1708-1712	were	_	_	_	_
12-17	1713-1721	directly	_	_	_	_
12-18	1722-1729	treated	_	_	_	_
12-19	1730-1734	with	_	_	_	_
12-20	1735-1739	H2O2	substance	new	coref	13-11
12-21	1740-1742	or	_	_	_	_
12-22	1743-1752	subjected	_	_	_	_
12-23	1753-1755	to	_	_	_	_
12-24	1756-1766	conditions	abstract	new	coref	20-52[170_0]
12-25	1767-1771	that	_	_	_	_
12-26	1772-1778	induce	_	_	_	_
12-27	1779-1788	secondary	abstract[95]	giv[95]	coref	14-32[119_95]
12-28	1789-1798	oxidative	event|abstract[95]	giv|giv[95]	coref	14-32
12-29	1799-1805	damage	abstract[95]	giv[95]	_	_
12-30	1806-1807	,	abstract[95]	giv[95]	_	_
12-31	1808-1812	such	abstract[95]	giv[95]	_	_
12-32	1813-1815	as	abstract[95]	giv[95]	_	_
12-33	1816-1819	UVA	abstract[95]|place|substance[97]	giv[95]|new|new[97]	_	_
12-34	1820-1831	irradiation	abstract[95]|substance[97]	giv[95]|new[97]	_	_
12-35	1832-1835	and	abstract[95]	giv[95]	_	_
12-36	1836-1843	ammonia	abstract[95]|substance|quantity[99]	giv[95]|new|new[99]	_	_
12-37	1844-1852	overload	abstract[95]|quantity[99]	giv[95]|new[99]	_	_
12-38	1853-1854	.	_	_	_	_

#Text=In one study , exposure of E. coli cells to H2O2 was shown to induce a dosage-dependent increase of 8-oxo-G in all tested RNA types , including rRNA .
13-1	1855-1857	In	_	_	_	_
13-2	1858-1861	one	abstract[100]	giv[100]	coref	14-19[115_100]
13-3	1862-1867	study	abstract[100]	giv[100]	_	_
13-4	1868-1869	,	_	_	_	_
13-5	1870-1878	exposure	event[101]	new[101]	_	_
13-6	1879-1881	of	event[101]	new[101]	_	_
13-7	1882-1884	E.	event[101]|object[102]	new[101]|giv[102]	coref	15-20[125_102]
13-8	1885-1889	coli	event[101]|object[102]	new[101]|giv[102]	_	_
13-9	1890-1895	cells	event[101]|object[102]	new[101]|giv[102]	_	_
13-10	1896-1898	to	event[101]|object[102]	new[101]|giv[102]	_	_
13-11	1899-1903	H2O2	event[101]|object[102]|substance	new[101]|giv[102]|giv	coref	14-8
13-12	1904-1907	was	_	_	_	_
13-13	1908-1913	shown	_	_	_	_
13-14	1914-1916	to	_	_	_	_
13-15	1917-1923	induce	_	_	_	_
13-16	1924-1925	a	abstract[104]	new[104]	_	_
13-17	1926-1942	dosage-dependent	abstract[104]	new[104]	_	_
13-18	1943-1951	increase	abstract[104]	new[104]	_	_
13-19	1952-1954	of	abstract[104]	new[104]	_	_
13-20	1955-1962	8-oxo-G	abstract[104]|quantity	new[104]|giv	coref	18-4[148_0]
13-21	1963-1965	in	_	_	_	_
13-22	1966-1969	all	place[107]	new[107]	_	_
13-23	1970-1976	tested	place[107]	new[107]	_	_
13-24	1977-1980	RNA	abstract|place[107]	giv|new[107]	coref	15-17[124_0]
13-25	1981-1986	types	place[107]	new[107]	_	_
13-26	1987-1988	,	place[107]	new[107]	_	_
13-27	1989-1998	including	place[107]	new[107]	_	_
13-28	1999-2003	rRNA	place[107]|abstract	new[107]|giv	coref	14-26
13-29	2004-2005	.	_	_	_	_

#Text=By comparing 8-oxo-G levels after in vitro H2O2 treatment of RNAs in their native and denatured forms , the same study concluded that folding of rRNA did not protect it against oxidative damage .
14-1	2006-2008	By	_	_	_	_
14-2	2009-2018	comparing	_	_	_	_
14-3	2019-2026	8-oxo-G	abstract[109]	new[109]	coref	18-1[147_109]
14-4	2027-2033	levels	abstract[109]	new[109]	_	_
14-5	2034-2039	after	_	_	_	_
14-6	2040-2042	in	_	_	_	_
14-7	2043-2048	vitro	event[111]	new[111]	_	_
14-8	2049-2053	H2O2	abstract|event[111]	giv|new[111]	_	_
14-9	2054-2063	treatment	event[111]	new[111]	_	_
14-10	2064-2066	of	event[111]	new[111]	_	_
14-11	2067-2071	RNAs	event[111]|substance	new[111]|new	ana	14-13
14-12	2072-2074	in	_	_	_	_
14-13	2075-2080	their	substance|abstract[114]	giv|new[114]	_	_
14-14	2081-2087	native	abstract[114]	new[114]	_	_
14-15	2088-2091	and	abstract[114]	new[114]	_	_
14-16	2092-2101	denatured	abstract[114]	new[114]	_	_
14-17	2102-2107	forms	abstract[114]	new[114]	_	_
14-18	2108-2109	,	_	_	_	_
14-19	2110-2113	the	abstract[115]	giv[115]	_	_
14-20	2114-2118	same	abstract[115]	giv[115]	_	_
14-21	2119-2124	study	abstract[115]	giv[115]	_	_
14-22	2125-2134	concluded	_	_	_	_
14-23	2135-2139	that	_	_	_	_
14-24	2140-2147	folding	_	_	_	_
14-25	2148-2150	of	_	_	_	_
14-26	2151-2155	rRNA	abstract	giv	ana	14-30
14-27	2156-2159	did	_	_	_	_
14-28	2160-2163	not	_	_	_	_
14-29	2164-2171	protect	_	_	_	_
14-30	2172-2174	it	abstract	giv	coref	20-19
14-31	2175-2182	against	_	_	_	_
14-32	2183-2192	oxidative	event|abstract[119]	giv|giv[119]	coref	20-47[168_119]
14-33	2193-2199	damage	abstract[119]	giv[119]	_	_
14-34	2200-2201	.	_	_	_	_

#Text=Similar conclusions were made by Willi and colleagues , who used an 8-oxo-G antibody to immunoprecipitate oxidized RNA from H2O2-treated E. coli cells .
15-1	2202-2209	Similar	abstract[120]	new[120]	_	_
15-2	2210-2221	conclusions	abstract[120]	new[120]	_	_
15-3	2222-2226	were	_	_	_	_
15-4	2227-2231	made	_	_	_	_
15-5	2232-2234	by	_	_	_	_
15-6	2235-2240	Willi	person	new	_	_
15-7	2241-2244	and	_	_	_	_
15-8	2245-2255	colleagues	person	new	_	_
15-9	2256-2257	,	_	_	_	_
15-10	2258-2261	who	_	_	_	_
15-11	2262-2266	used	_	_	_	_
15-12	2267-2269	an	object[123]	new[123]	_	_
15-13	2270-2277	8-oxo-G	object[123]	new[123]	_	_
15-14	2278-2286	antibody	object[123]	new[123]	_	_
15-15	2287-2289	to	_	_	_	_
15-16	2290-2307	immunoprecipitate	_	_	_	_
15-17	2308-2316	oxidized	substance[124]	giv[124]	coref	16-11[129_124]
15-18	2317-2320	RNA	substance[124]	giv[124]	_	_
15-19	2321-2325	from	_	_	_	_
15-20	2326-2338	H2O2-treated	object[125]	giv[125]	_	_
15-21	2339-2341	E.	object[125]	giv[125]	_	_
15-22	2342-2346	coli	object[125]	giv[125]	_	_
15-23	2347-2352	cells	object[125]	giv[125]	_	_
15-24	2353-2354	.	_	_	_	_

#Text=A large body of observations points to the association of oxidized RNA with disease .
16-1	2355-2356	A	object[126]	new[126]	coref	17-38[0_126]
16-2	2357-2362	large	object[126]	new[126]	_	_
16-3	2363-2367	body	object[126]	new[126]	_	_
16-4	2368-2370	of	object[126]	new[126]	_	_
16-5	2371-2383	observations	object[126]|abstract	new[126]|new	_	_
16-6	2384-2390	points	_	_	_	_
16-7	2391-2393	to	_	_	_	_
16-8	2394-2397	the	abstract[128]	new[128]	_	_
16-9	2398-2409	association	abstract[128]	new[128]	_	_
16-10	2410-2412	of	abstract[128]	new[128]	_	_
16-11	2413-2421	oxidized	abstract[128]|substance[129]	new[128]|giv[129]	coref	17-7[133_129]
16-12	2422-2425	RNA	abstract[128]|substance[129]	new[128]|giv[129]	_	_
16-13	2426-2430	with	abstract[128]|substance[129]	new[128]|giv[129]	_	_
16-14	2431-2438	disease	abstract[128]|substance[129]|abstract	new[128]|giv[129]|new	coref	17-15[136_0]
16-15	2439-2440	.	_	_	_	_

#Text=High 8-oxo-G content in cytoplasmic and nucleolar RNA was found in vulnerable neurons in Alzheimer′s disease ( AD ) , Parkinson ’s disease , and neurons of the hippocampal region and temporal neocortex in patients with Lewy body dementia .
17-1	2441-2445	High	abstract[131]	giv[131]	_	_
17-2	2446-2453	8-oxo-G	abstract[131]	giv[131]	_	_
17-3	2454-2461	content	abstract[131]	giv[131]	_	_
17-4	2462-2464	in	abstract[131]	giv[131]	_	_
17-5	2465-2476	cytoplasmic	abstract[131]|abstract	giv[131]|new	_	_
17-6	2477-2480	and	abstract[131]	giv[131]	_	_
17-7	2481-2490	nucleolar	abstract[131]|substance[133]	giv[131]|giv[133]	coref	18-6[0_133]
17-8	2491-2494	RNA	abstract[131]|substance[133]	giv[131]|giv[133]	_	_
17-9	2495-2498	was	_	_	_	_
17-10	2499-2504	found	_	_	_	_
17-11	2505-2507	in	_	_	_	_
17-12	2508-2518	vulnerable	place[134]	new[134]	_	_
17-13	2519-2526	neurons	place[134]	new[134]	_	_
17-14	2527-2529	in	place[134]	new[134]	_	_
17-15	2530-2541	Alzheimer′s	place[134]|place|abstract[136]	new[134]|new|giv[136]	appos	17-18[0_136]
17-16	2542-2549	disease	place[134]|abstract[136]	new[134]|giv[136]	_	_
17-17	2550-2551	(	_	_	_	_
17-18	2552-2554	AD	abstract	giv	coref	17-21[139_0]
17-19	2555-2556	)	_	_	_	_
17-20	2557-2558	,	_	_	_	_
17-21	2559-2568	Parkinson	person[138]|abstract[139]	new[138]|giv[139]	coref	21-21[0_139]
17-22	2569-2571	’s	person[138]|abstract[139]	new[138]|giv[139]	_	_
17-23	2572-2579	disease	abstract[139]	giv[139]	_	_
17-24	2580-2581	,	_	_	_	_
17-25	2582-2585	and	_	_	_	_
17-26	2586-2593	neurons	place[140]	new[140]	_	_
17-27	2594-2596	of	place[140]	new[140]	_	_
17-28	2597-2600	the	place[140]|place[141]	new[140]|new[141]	_	_
17-29	2601-2612	hippocampal	place[140]|place[141]	new[140]|new[141]	_	_
17-30	2613-2619	region	place[140]|place[141]	new[140]|new[141]	_	_
17-31	2620-2623	and	place[140]	new[140]	_	_
17-32	2624-2632	temporal	place[140]|abstract[142]	new[140]|new[142]	_	_
17-33	2633-2642	neocortex	place[140]|abstract[142]	new[140]|new[142]	_	_
17-34	2643-2645	in	place[140]|abstract[142]	new[140]|new[142]	_	_
17-35	2646-2654	patients	place[140]|abstract[142]|person[143]	new[140]|new[142]|new[143]	coref	21-19[176_143]
17-36	2655-2659	with	place[140]|abstract[142]|person[143]	new[140]|new[142]|new[143]	_	_
17-37	2660-2664	Lewy	place[140]|abstract[142]|person[143]|person|abstract[146]	new[140]|new[142]|new[143]|new|new[146]	_	_
17-38	2665-2669	body	place[140]|abstract[142]|person[143]|object|abstract[146]	new[140]|new[142]|new[143]|giv|new[146]	_	_
17-39	2670-2678	dementia	place[140]|abstract[142]|person[143]|abstract[146]	new[140]|new[142]|new[143]|new[146]	_	_
17-40	2679-2680	.	_	_	_	_

#Text=Elevated levels of 8-oxo-G in RNA were also detected in neuropsychiatric disorders , including schizophrenia , depressive , and bipolar disorders .
18-1	2681-2689	Elevated	abstract[147]	giv[147]	_	_
18-2	2690-2696	levels	abstract[147]	giv[147]	_	_
18-3	2697-2699	of	abstract[147]	giv[147]	_	_
18-4	2700-2707	8-oxo-G	abstract[147]|abstract[148]	giv[147]|giv[148]	coref	19-12[0_148]
18-5	2708-2710	in	abstract[147]|abstract[148]	giv[147]|giv[148]	_	_
18-6	2711-2714	RNA	abstract[147]|abstract[148]|substance	giv[147]|giv[148]|giv	coref	19-3
18-7	2715-2719	were	_	_	_	_
18-8	2720-2724	also	_	_	_	_
18-9	2725-2733	detected	_	_	_	_
18-10	2734-2736	in	_	_	_	_
18-11	2737-2753	neuropsychiatric	abstract[150]	new[150]	_	_
18-12	2754-2763	disorders	abstract[150]	new[150]	_	_
18-13	2764-2765	,	abstract[150]	new[150]	_	_
18-14	2766-2775	including	abstract[150]	new[150]	_	_
18-15	2776-2789	schizophrenia	abstract[150]|abstract	new[150]|new	_	_
18-16	2790-2791	,	abstract[150]	new[150]	_	_
18-17	2792-2802	depressive	abstract[150]|abstract	new[150]|new	_	_
18-18	2803-2804	,	abstract[150]	new[150]	_	_
18-19	2805-2808	and	abstract[150]	new[150]	_	_
18-20	2809-2816	bipolar	abstract[150]|abstract[153]	new[150]|new[153]	_	_
18-21	2817-2826	disorders	abstract[150]|abstract[153]	new[150]|new[153]	_	_
18-22	2827-2828	.	_	_	_	_

#Text=Furthermore , RNA extracted from atherosclerotic plaques was heavily modified with 8-oxo-G .
19-1	2829-2840	Furthermore	_	_	_	_
19-2	2841-2842	,	_	_	_	_
19-3	2843-2846	RNA	substance	giv	coref	20-16[161_0]
19-4	2847-2856	extracted	_	_	_	_
19-5	2857-2861	from	_	_	_	_
19-6	2862-2877	atherosclerotic	substance|object[156]	new|new[156]	_	_
19-7	2878-2885	plaques	object[156]	new[156]	_	_
19-8	2886-2889	was	_	_	_	_
19-9	2890-2897	heavily	_	_	_	_
19-10	2898-2906	modified	_	_	_	_
19-11	2907-2911	with	_	_	_	_
19-12	2912-2919	8-oxo-G	substance	giv	_	_
19-13	2920-2921	.	_	_	_	_

#Text=Although links between 8-oxo-G and human pathologies have been based largely on the analysis of total RNA , rRNA is the most abundant cellular RNA type , which typically accounts for about 80 % of the total RNA , from which one can reasonably assume that oxidative damage to ribosomes in all these pathological conditions must be widespread .
20-1	2922-2930	Although	_	_	_	_
20-2	2931-2936	links	abstract[158]	new[158]	_	_
20-3	2937-2944	between	abstract[158]	new[158]	_	_
20-4	2945-2952	8-oxo-G	abstract[158]|abstract[159]	new[158]|new[159]	_	_
20-5	2953-2956	and	abstract[158]|abstract[159]	new[158]|new[159]	_	_
20-6	2957-2962	human	abstract[158]|abstract[159]	new[158]|new[159]	_	_
20-7	2963-2974	pathologies	abstract[158]|abstract[159]	new[158]|new[159]	_	_
20-8	2975-2979	have	_	_	_	_
20-9	2980-2984	been	_	_	_	_
20-10	2985-2990	based	_	_	_	_
20-11	2991-2998	largely	_	_	_	_
20-12	2999-3001	on	_	_	_	_
20-13	3002-3005	the	abstract[160]	new[160]	_	_
20-14	3006-3014	analysis	abstract[160]	new[160]	_	_
20-15	3015-3017	of	abstract[160]	new[160]	_	_
20-16	3018-3023	total	abstract[160]|substance[161]	new[160]|giv[161]	coref	20-25[0_161]
20-17	3024-3027	RNA	abstract[160]|substance[161]	new[160]|giv[161]	_	_
20-18	3028-3029	,	_	_	_	_
20-19	3030-3034	rRNA	abstract	giv	coref	20-21[164_0]
20-20	3035-3037	is	_	_	_	_
20-21	3038-3041	the	abstract[164]	giv[164]	ana	20-42[0_164]
20-22	3042-3046	most	abstract[164]	giv[164]	_	_
20-23	3047-3055	abundant	abstract[164]	giv[164]	_	_
20-24	3056-3064	cellular	abstract[164]	giv[164]	_	_
20-25	3065-3068	RNA	substance|abstract[164]	giv|giv[164]	coref	20-36[166_0]
20-26	3069-3073	type	abstract[164]	giv[164]	_	_
20-27	3074-3075	,	_	_	_	_
20-28	3076-3081	which	_	_	_	_
20-29	3082-3091	typically	_	_	_	_
20-30	3092-3100	accounts	_	_	_	_
20-31	3101-3104	for	_	_	_	_
20-32	3105-3110	about	quantity[165]	new[165]	_	_
20-33	3111-3113	80	quantity[165]	new[165]	_	_
20-34	3114-3115	%	quantity[165]	new[165]	_	_
20-35	3116-3118	of	quantity[165]	new[165]	_	_
20-36	3119-3122	the	quantity[165]|substance[166]	new[165]|giv[166]	_	_
20-37	3123-3128	total	quantity[165]|substance[166]	new[165]|giv[166]	_	_
20-38	3129-3132	RNA	quantity[165]|substance[166]	new[165]|giv[166]	_	_
20-39	3133-3134	,	_	_	_	_
20-40	3135-3139	from	_	_	_	_
20-41	3140-3145	which	_	_	_	_
20-42	3146-3149	one	abstract	giv	coref	21-6
20-43	3150-3153	can	_	_	_	_
20-44	3154-3164	reasonably	_	_	_	_
20-45	3165-3171	assume	_	_	_	_
20-46	3172-3176	that	_	_	_	_
20-47	3177-3186	oxidative	abstract[168]	giv[168]	_	_
20-48	3187-3193	damage	abstract[168]	giv[168]	_	_
20-49	3194-3196	to	abstract[168]	giv[168]	_	_
20-50	3197-3206	ribosomes	abstract[168]|object	giv[168]|new	_	_
20-51	3207-3209	in	_	_	_	_
20-52	3210-3213	all	abstract[170]	giv[170]	_	_
20-53	3214-3219	these	abstract[170]	giv[170]	_	_
20-54	3220-3232	pathological	abstract[170]	giv[170]	_	_
20-55	3233-3243	conditions	abstract[170]	giv[170]	_	_
20-56	3244-3248	must	_	_	_	_
20-57	3249-3251	be	_	_	_	_
20-58	3252-3262	widespread	_	_	_	_
20-59	3263-3264	.	_	_	_	_

#Text=Studies that focused specifically on rRNA confirmed it to be a major target of the 8-oxo-G modification in patients with AD and mild cognitive impairment , a condition that often precedes AD .
21-1	3265-3272	Studies	abstract	new	_	_
21-2	3273-3277	that	_	_	_	_
21-3	3278-3285	focused	_	_	_	_
21-4	3286-3298	specifically	_	_	_	_
21-5	3299-3301	on	_	_	_	_
21-6	3302-3306	rRNA	abstract	giv	ana	21-8
21-7	3307-3316	confirmed	_	_	_	_
21-8	3317-3319	it	abstract	giv	_	_
21-9	3320-3322	to	_	_	_	_
21-10	3323-3325	be	_	_	_	_
21-11	3326-3327	a	abstract[174]	new[174]	_	_
21-12	3328-3333	major	abstract[174]	new[174]	_	_
21-13	3334-3340	target	abstract[174]	new[174]	_	_
21-14	3341-3343	of	abstract[174]	new[174]	_	_
21-15	3344-3347	the	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-16	3348-3355	8-oxo-G	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-17	3356-3368	modification	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-18	3369-3371	in	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-19	3372-3380	patients	abstract[174]|abstract[175]|person[176]	new[174]|giv[175]|giv[176]	_	_
21-20	3381-3385	with	abstract[174]|abstract[175]|person[176]	new[174]|giv[175]|giv[176]	_	_
21-21	3386-3388	AD	abstract[174]|abstract[175]|person[176]|abstract	new[174]|giv[175]|giv[176]|giv	coref	21-32
21-22	3389-3392	and	abstract[174]|abstract[175]|person[176]	new[174]|giv[175]|giv[176]	_	_
21-23	3393-3397	mild	abstract[174]|abstract[175]|person[176]|abstract[178]	new[174]|giv[175]|giv[176]|new[178]	_	_
21-24	3398-3407	cognitive	abstract[174]|abstract[175]|person[176]|abstract[178]	new[174]|giv[175]|giv[176]|new[178]	_	_
21-25	3408-3418	impairment	abstract[174]|abstract[175]|person[176]|abstract[178]	new[174]|giv[175]|giv[176]|new[178]	_	_
21-26	3419-3420	,	abstract[174]|abstract[175]|person[176]	new[174]|giv[175]|giv[176]	_	_
21-27	3421-3422	a	abstract[174]|abstract[175]|person[176]|abstract[179]	new[174]|giv[175]|giv[176]|new[179]	_	_
21-28	3423-3432	condition	abstract[174]|abstract[175]|person[176]|abstract[179]	new[174]|giv[175]|giv[176]|new[179]	_	_
21-29	3433-3437	that	_	_	_	_
21-30	3438-3443	often	_	_	_	_
21-31	3444-3452	precedes	_	_	_	_
21-32	3453-3455	AD	abstract	giv	_	_
21-33	3456-3457	.	_	_	_	_
